<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;fc=20230708114047&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Sun, 17 Nov 2024 20:11:15 +0000</lastbuilddate>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>The Fine Art and Science of Translating Trials Results Into Clinical Practice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550722/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4550. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550722/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39550722</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4550>10.1001/jamacardio.2024.4550</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550722</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:creator>Eric D Peterson</dc:creator>
<dc:creator>Adrian F Hernandez</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>The Fine Art and Science of Translating Trials Results Into Clinical Practice</dc:title>
<dc:identifier>pmid:39550722</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4550</dc:identifier>
</item>
<item>
<title>Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550721/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In FINEARTS-HF, finerenone reduced the risk of the primary end point similarly in women and men with heart failure with mildly reduced or preserved ejection fraction. Finerenone had similar tolerability in women and men.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4613. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Sex is associated with the clinical presentation, outcomes, and response to treatment in patients with heart failure (HF). However, little is known about the safety and efficacy of treatment with finerenone according to sex.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To estimate the efficacy and safety of finerenone compared with placebo in both women and men.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Prespecified analyses were conducted in the phase 3 randomized clinical trial Finerenone Trial to Investigate Efficacy and Safety Superior to Placebo in Patients with Heart Failure (FINEARTS-HF). The trial was conducted across 653 sites in 37 countries. Participants were adults aged 40 years and older with symptomatic HF and left ventricular ejection fraction (LVEF) of 40% or greater randomized between September 2020 and January 2023.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Finerenone (titrated to 20 mg or 40 mg) or placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of cardiovascular death and total (first and recurrent) HF events (unplanned HF hospitalizations or urgent HF visits).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 6001 patients were randomized in FINEARTS-HF, of whom 2732 were women (45.5%), with a mean (SD) age of 73.6 (9.1) years. Women had higher rates of any obesity, higher LVEF (54.6 [7.6%] vs 50.9 [7.6] for men), lower mean (SD) estimated glomerular filtration rate than men (59.7 [19.1] vs 64.1 [20.0] for men; P&lt;.001) , worse New York Heart Association functional class, and lower Kansas City Cardiomyopathy Questionnaire-Total Symptom Scores (KCCQ-TSS) (mean [SD] 62.3 [24.0] vs 71.0 [23.1]). The incident rate of the primary outcome was slightly lower in women (15.7; 95% CI, 14.3-17.3) than in men (16.8; 95% CI, 15.4-18.3) per 100 person-years. Compared with placebo, finerenone reduced the risk of the primary end point similarly in women and men: rate ratio 0.78 (95% CI, 0.65-0.95) in women and 0.88 (95% CI, 0.74-1.04) in men (P = .41 for interaction). Consistent effects were observed for the components of the primary outcome and all-cause mortality. The mean increase (improvement) in KCCQ-TSS from baseline to 12 months was greater with finerenone, regardless of sex (P = .73 for interaction). Finerenone had similar tolerability in women and men.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In FINEARTS-HF, finerenone reduced the risk of the primary end point similarly in women and men with heart failure with mildly reduced or preserved ejection fraction. Finerenone had similar tolerability in women and men.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550721/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39550721</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4613>10.1001/jamacardio.2024.4613</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550721</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Misato Chimura</dc:creator>
<dc:creator>Xiaowen Wang</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Alasdair D Henderson</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Cândida Fonseca</dc:creator>
<dc:creator>Eva Goncalvesova</dc:creator>
<dc:creator>Tzvetana Katova</dc:creator>
<dc:creator>Katharina Mueller</dc:creator>
<dc:creator>Andrea Glasauer</dc:creator>
<dc:creator>Katja Rohwedder</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Savina Nodari</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Clara Inés Saldarriaga</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Kavita Sharma</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Orly Vardeny</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Finerenone in Women and Men With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Secondary Analysis of the FINEARTS-HF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39550721</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4613</dc:identifier>
</item>
<item>
<title>Partial Cardiac Denervation to Prevent Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: The pCAD-POAF Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550720/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that partial cardiac denervation was an effective procedure to reduce the occurrence of POAF after isolated CABG without additional postoperative complications. These results suggest that partial cardiac denervation may be a good option for cardiac surgeons to consider for preventing POAF after CABG.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4639. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Efficient approaches to prevent postoperative atrial fibrillation (POAF) after coronary artery bypass grafting (CABG) are still needed.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate whether partial cardiac denervation, achieved by cutting off the ligament of Marshall (LOM) and resecting the fat pad along the Waterston groove, can reduce the risk of POAF following CABG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING AND PARTICIPANTS: This single-center, randomized clinical trial enrolled adult patients scheduled for isolated CABG in China. Enrollment was from August 15, 2022, to December 13, 2023; follow-up visits were 30 days after discharge.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Participants were randomized into the intervention group (CABG plus partial cardiac denervation) and the control group (CABG only) in a 1:1 pattern. All participants were continuously monitored for the incidence of POAF until day 6 after the operation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: The primary end point was the incidence of POAF in 6 days, defined as a supraventricular arrhythmia lasting for more than 30 seconds.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The trial enrolled 430 patients (79 [18.4%] female; mean [SD] age, 61.9 [7.8] years). Compared with the control group, the 6-day incidence of POAF was significantly lower in the intervention group (18.1% vs 31.6%; P = .001; risk ratio, 0.57 [95% CI, 0.41-0.81]). To further support these results, a sensitivity analysis performed with Kaplan-Meier survival curves also showed a significant reduction in the occurrence of POAF in the intervention group (hazard ratio, 0.53 [95% CI, 0.36-0.79]; P = .002). Safety assessments showed no difference between the 2 groups, while postoperative medical cost was reduced in the intervention group.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: This randomized clinical trial found that partial cardiac denervation was an effective procedure to reduce the occurrence of POAF after isolated CABG without additional postoperative complications. These results suggest that partial cardiac denervation may be a good option for cardiac surgeons to consider for preventing POAF after CABG.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05009914.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550720/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39550720</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4639>10.1001/jamacardio.2024.4639</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550720</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Ziang Yang</dc:creator>
<dc:creator>Xieraili Tiemuerniyazi</dc:creator>
<dc:creator>Fei Xu</dc:creator>
<dc:creator>Yang Wang</dc:creator>
<dc:creator>Yang Sun</dc:creator>
<dc:creator>Peng Yan</dc:creator>
<dc:creator>Liangxin Tian</dc:creator>
<dc:creator>Chao Han</dc:creator>
<dc:creator>Yan Zhang</dc:creator>
<dc:creator>Shiwei Pan</dc:creator>
<dc:creator>Zhan Hu</dc:creator>
<dc:creator>Xi Li</dc:creator>
<dc:creator>Wei Zhao</dc:creator>
<dc:creator>Wei Feng</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Partial Cardiac Denervation to Prevent Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting: The pCAD-POAF Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:39550720</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4639</dc:identifier>
</item>
<item>
<title>Sex-Specific Efficacy and Safety in HF Trials: Inclusion Is Only the First Step</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550719/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4624. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550719/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39550719</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4624>10.1001/jamacardio.2024.4624</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550719</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Sadiya Khan</dc:creator>
<dc:creator>Clyde W Yancy</dc:creator>
<dc:creator>Gregg C Fonarow</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Sex-Specific Efficacy and Safety in HF Trials: Inclusion Is Only the First Step</dc:title>
<dc:identifier>pmid:39550719</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4624</dc:identifier>
</item>
<item>
<title>Power of Digital Nudges to Boost Influenza Vaccination Rates</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550718/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4692. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550718/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39550718</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4692>10.1001/jamacardio.2024.4692</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550718</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Mohammad Madjid</dc:creator>
<dc:creator>Payam Safavi-Naeini</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Power of Digital Nudges to Boost Influenza Vaccination Rates</dc:title>
<dc:identifier>pmid:39550718</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4692</dc:identifier>
</item>
<item>
<title>Electronic Nudges and Influenza Vaccination Among Patients With a History of Myocardial Infarction: Insights From 3 Nationwide Randomized Clinical Trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550717/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: Across 3 nationwide RCTs of Danish citizens, messaging emphasizing the cardiovascular benefits of vaccination improved influenza vaccination uptake, with greater benefits observed in patients with a history of AMI. This low-cost, scalable implementation strategy should be considered to encourage influenza vaccination in high-risk patients.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4648. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Influenza vaccination in patients with acute myocardial infarction (AMI) reduces major adverse cardiac events and is strongly recommended in clinical practice guidelines. Effective strategies to improve vaccination are needed in these high-risk patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To evaluate whether electronically delivered behavioral nudges improve influenza vaccine uptake in patients with AMI across 3 nationwide implementation randomized clinical trials (RCTs).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Nationwide Utilization of Danish Government Electronic Letter System for Increasing Influenza Vaccine Uptake (NUDGE-FLU), Nationwide Utilization of Danish Government Electronic Letter System for Confirming the Effectiveness of Behavioral Nudges in Increasing Influenza Vaccine Uptake Among Older Adults (NUDGE-FLU-2), and Nationwide Utilization of Danish Government Electronic Letter System for Increasing Influenza Vaccine Uptake Among Adults With Chronic Disease (NUDGE-FLU-CHRONIC) were RCTs conducted during the 2022 to 2023 and 2023 to 2024 influenza seasons in Denmark. Participants were randomized to either usual care or various behaviorally informed, electronically delivered, letter-based nudges. In a prespecified participant-level pooled meta-analysis, interaction of AMI status on the effects of letter-based nudges vs usual care was examined. Pooled treatment effects were estimated using binomial regression models with identity link, adjustment for trial, and 2-way clustered SEs at the household and participant levels. Effect modification by recency of AMI as a continuous variable was assessed using restricted cubic spline modeling in NUDGE-FLU-CHRONIC.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Behaviorally informed, electronically delivered, letter-based nudges or usual care.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOME AND MEASURES: The primary end point was influenza vaccination receipt.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 2 146 124 individual randomizations (mean [SD] age, 71.1 [11.6] years; 1 114 725 female [51.9%]) across all 3 trials, 59 458 (2.8%) had a history of AMI. Improvement in vaccine uptake was similar in patients with vs without a history of AMI who received any nudge letter compared with usual care (+1.81 vs +1.32 percentage points; P for interaction by AMI status = .09). A letter highlighting the cardiovascular benefits of vaccination (ie, cardiovascular-gain frame) resulted in larger improvements in vaccine uptake among patients with (vs without) a history of AMI (+3.91 vs +2.03 percentage points; P for interaction by AMI status = .002). Among patients with AMI, the benefits of the cardiovascular-gain frame letter were more pronounced in those not vaccinated in the prior season (+13.7 vs +1.48 percentage points; P for interaction &lt;.001). Among younger participants with chronic disease, the cardiovascular-gain frame letter was particularly effective in patients with more recent AMI (P for interaction by continuous recency of AMI &lt;.001).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: Across 3 nationwide RCTs of Danish citizens, messaging emphasizing the cardiovascular benefits of vaccination improved influenza vaccination uptake, with greater benefits observed in patients with a history of AMI. This low-cost, scalable implementation strategy should be considered to encourage influenza vaccination in high-risk patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT05542004, NCT06030726, NCT06030739.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550717/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39550717</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4648>10.1001/jamacardio.2024.4648</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550717</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Ankeet S Bhatt</dc:creator>
<dc:creator>Niklas Dyrby Johansen</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Daniel Modin</dc:creator>
<dc:creator>Manan Pareek</dc:creator>
<dc:creator>Safia Chatur</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Kira Hyldekær Janstrup</dc:creator>
<dc:creator>Carsten Schade Larsen</dc:creator>
<dc:creator>Lykke Larsen</dc:creator>
<dc:creator>Lothar Wiese</dc:creator>
<dc:creator>Michael Dalager-Pedersen</dc:creator>
<dc:creator>Erica L Dueger</dc:creator>
<dc:creator>Sandrine Samson</dc:creator>
<dc:creator>Matthew M Loiacono</dc:creator>
<dc:creator>Rebecca C Harris</dc:creator>
<dc:creator>Lars Køber</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:creator>Cyril Jean-Marie Martel</dc:creator>
<dc:creator>Pradeesh Sivapalan</dc:creator>
<dc:creator>Jens Ulrik Stæhr Jensen</dc:creator>
<dc:creator>Tor Biering-Sørensen</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Electronic Nudges and Influenza Vaccination Among Patients With a History of Myocardial Infarction: Insights From 3 Nationwide Randomized Clinical Trials</dc:title>
<dc:identifier>pmid:39550717</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4648</dc:identifier>
</item>
<item>
<title>Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39550716/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS AND RELEVANCE: In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone resulted in more frequent hyperkalemia and less frequent hypokalemia. However, with protocol-directed surveillance and dose adjustment, clinical benefit associated with finerenone relative to placebo was maintained even in those whose potassium level increased to greater than 5.5 mmol/L.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 17. doi: 10.1001/jamacardio.2024.4539. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Treatment with finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), improved outcomes in patients with heart failure with mildly reduced or preserved ejection fraction in FINEARTS-HF, but was associated with increased levels of serum potassium in follow-up.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To investigate the frequency and predictors of serum potassium level greater than 5.5 mmol/L and less than 3.5 mmol/L and examine the treatment effect associated with finerenone, relative to placebo, on clinical outcomes based on postrandomization potassium levels.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: Secondary analysis of the FINEARTS-HF multicenter, randomized clinical trial, performed between September 14, 2020, and January 10, 2023, with a median follow-up of 32 months (final date of follow-up: June 14, 2024). Patients with heart failure and left ventricular ejection fraction greater than or equal to 40%, New York Heart Association class II to IV symptoms, and elevated natriuretic peptides were included.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTION: Participants received finerenone or placebo.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary outcome was a composite of total worsening heart failure events or cardiovascular death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 6001 participants were included (3003 randomized to receive finerenone and 2998 randomized to receive placebo). The increase in serum potassium was greater in the finerenone group than the placebo group at 1 month (median [IQR] difference, 0.19 [0.17-0.21] mmol/L) and 3 months (median [IQR] difference, 0.23 [0.21-0.25] mmol/L), which persisted for the remainder of trial follow-up. Finerenone increased the risks of potassium level increasing to greater than 5.5 mmol/L (hazard ratio [HR], 2.16 [95% CI, 1.83-2.56]; P &lt; .001) and decreased the risks for potassium level decreasing to less than 3.5 mmol/L (HR, 0.46 [95% CI, 0.38-0.56]; P &lt; .001). Both low (&lt; 3.5 mmol/L; HR, 2.49 [95% CI, 1.8-3.43]) and high (>;5.5 mmol/L; HR, 1.64 [95% CI, 1.04-2.58]) potassium levels were associated with higher subsequent risks of the primary outcome in both treatment groups. Nevertheless, the risk of the primary outcome was generally lower in patients treated with finerenone compared with placebo, even in those whose potassium level increased to greater than 5.5 mmol/L.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: In patients with heart failure with mildly reduced or preserved ejection fraction, finerenone resulted in more frequent hyperkalemia and less frequent hypokalemia. However, with protocol-directed surveillance and dose adjustment, clinical benefit associated with finerenone relative to placebo was maintained even in those whose potassium level increased to greater than 5.5 mmol/L.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04435626.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39550716/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39550716</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4539>10.1001/jamacardio.2024.4539</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39550716</guid>
<pubDate>Sun, 17 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Orly Vardeny</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:creator>Brian L Claggett</dc:creator>
<dc:creator>Akshay S Desai</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Carolyn S P Lam</dc:creator>
<dc:creator>Michele Senni</dc:creator>
<dc:creator>Sanjiv J Shah</dc:creator>
<dc:creator>Adriaan A Voors</dc:creator>
<dc:creator>Faiez Zannad</dc:creator>
<dc:creator>Bertram Pitt</dc:creator>
<dc:creator>Shingo Matsumoto</dc:creator>
<dc:creator>Béla Merkely</dc:creator>
<dc:creator>Shelley Zieroth</dc:creator>
<dc:creator>Mehmet Birhan Yilmaz</dc:creator>
<dc:creator>James Lay-Flurrie</dc:creator>
<dc:creator>Prabhakar Viswanathan</dc:creator>
<dc:creator>Andrea Horvat-Broecker</dc:creator>
<dc:creator>Andrea Scalise</dc:creator>
<dc:creator>John J V McMurray</dc:creator>
<dc:creator>Scott D Solomon</dc:creator>
<dc:date>2024-11-17</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Finerenone, Serum Potassium, and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:39550716</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4539</dc:identifier>
</item>
<item>
<title>The Arabidopsis blue-light photoreceptor CRY2 is active in darkness to inhibit root growth</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39549699/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>Cryptochromes (CRYs) are blue-light receptors that regulate diverse aspects of plant growth. However, whether and how non-photoexcited CRYs function in darkness or non-blue-light conditions is unknown. Here, we show that CRY2 affects the Arabidopsis transcriptome even in darkness, revealing a non-canonical function. CRY2 suppresses cell division in the root apical meristem to downregulate root elongation in darkness. Blue-light oligomerizes CRY2 to de-repress root elongation. CRY2 physically...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 8:S0092-8674(24)01213-3. doi: 10.1016/j.cell.2024.10.031. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cryptochromes (CRYs) are blue-light receptors that regulate diverse aspects of plant growth. However, whether and how non-photoexcited CRYs function in darkness or non-blue-light conditions is unknown. Here, we show that CRY2 affects the Arabidopsis transcriptome even in darkness, revealing a non-canonical function. CRY2 suppresses cell division in the root apical meristem to downregulate root elongation in darkness. Blue-light oligomerizes CRY2 to de-repress root elongation. CRY2 physically interacts with FORKED-LIKE 1 (FL1) and FL3, and these interactions are inhibited by blue light, with only monomeric but not dimeric CRY2 able to interact. FL1 and FL3 associate with the chromatin of cell division genes to facilitate their transcription. This pro-growth activity is inhibited by CRY2's physical interaction with FLs in darkness. Plants have evolved to perceive both blue-light and dark cues to coordinate activation and repression of competing developmental processes in above- and below-ground organs through economical and dichotomous use of ancient light receptors.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39549699/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39549699</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.031>10.1016/j.cell.2024.10.031</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39549699</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Desheng Zeng</dc:creator>
<dc:creator>Junqing Lv</dc:creator>
<dc:creator>Xu Li</dc:creator>
<dc:creator>Hongtao Liu</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The Arabidopsis blue-light photoreceptor CRY2 is active in darkness to inhibit root growth</dc:title>
<dc:identifier>pmid:39549699</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.031</dc:identifier>
</item>
<item>
<title>The single-molecule accessibility landscape of newly replicated mammalian chromatin</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39549698/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>We present replication-aware single-molecule accessibility mapping (RASAM), a method to nondestructively measure replication status and protein-DNA interactions on chromatin genome-wide. Using RASAM, we uncover a genome-wide state of single-molecule "hyperaccessibility" post-replication that resolves over several hours. Combining RASAM with cellular models for rapid protein degradation, we demonstrate that histone chaperone CAF-1 reduces nascent chromatin accessibility by filling...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 12:S0092-8674(24)01255-8. doi: 10.1016/j.cell.2024.10.039. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">We present replication-aware single-molecule accessibility mapping (RASAM), a method to nondestructively measure replication status and protein-DNA interactions on chromatin genome-wide. Using RASAM, we uncover a genome-wide state of single-molecule "hyperaccessibility" post-replication that resolves over several hours. Combining RASAM with cellular models for rapid protein degradation, we demonstrate that histone chaperone CAF-1 reduces nascent chromatin accessibility by filling single-molecular "gaps" and generating closely spaced dinucleosomes on replicated DNA. At cis-regulatory elements, we observe unique modes by which nascent chromatin hyperaccessibility resolves: at CCCTC-binding factor (CTCF)-binding sites, CTCF and nucleosomes compete, reducing CTCF occupancy and motif accessibility post-replication; at active transcription start sites, high chromatin accessibility is maintained, implying rapid re-establishment of nucleosome-free regions. Our study introduces a new paradigm for studying replicated chromatin fiber organization. More broadly, we uncover a unique organization of newly replicated chromatin that must be reset by active processes, providing a substrate for epigenetic reprogramming.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39549698/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39549698</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.039>10.1016/j.cell.2024.10.039</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39549698</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Megan S Ostrowski</dc:creator>
<dc:creator>Marty G Yang</dc:creator>
<dc:creator>Colin P McNally</dc:creator>
<dc:creator>Nour J Abdulhay</dc:creator>
<dc:creator>Simai Wang</dc:creator>
<dc:creator>Keerthi Renduchintala</dc:creator>
<dc:creator>Iryna Irkliyenko</dc:creator>
<dc:creator>Alva Biran</dc:creator>
<dc:creator>Brandon T L Chew</dc:creator>
<dc:creator>Ayush D Midha</dc:creator>
<dc:creator>Emily V Wong</dc:creator>
<dc:creator>Jonathan Sandoval</dc:creator>
<dc:creator>Isha H Jain</dc:creator>
<dc:creator>Anja Groth</dc:creator>
<dc:creator>Elphège P Nora</dc:creator>
<dc:creator>Hani Goodarzi</dc:creator>
<dc:creator>Vijay Ramani</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The single-molecule accessibility landscape of newly replicated mammalian chromatin</dc:title>
<dc:identifier>pmid:39549698</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.039</dc:identifier>
</item>
<item>
<title>Stress disrupts engram ensembles in lateral amygdala to generalize threat memory in mice</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39549697/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>Stress induces aversive memory overgeneralization, a hallmark of many psychiatric disorders. Memories are encoded by a sparse ensemble of neurons active during an event (an engram ensemble). We examined the molecular and circuit processes mediating stress-induced threat memory overgeneralization in mice. Stress, acting via corticosterone, increased the density of engram ensembles supporting a threat memory in lateral amygdala, and this engram ensemble was reactivated by both specific and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 12:S0092-8674(24)01216-9. doi: 10.1016/j.cell.2024.10.034. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Stress induces aversive memory overgeneralization, a hallmark of many psychiatric disorders. Memories are encoded by a sparse ensemble of neurons active during an event (an engram ensemble). We examined the molecular and circuit processes mediating stress-induced threat memory overgeneralization in mice. Stress, acting via corticosterone, increased the density of engram ensembles supporting a threat memory in lateral amygdala, and this engram ensemble was reactivated by both specific and non-specific retrieval cues (generalized threat memory). Furthermore, we identified a critical role for endocannabinoids, acting retrogradely on parvalbumin-positive (PV+) lateral amygdala interneurons in the formation of a less-sparse engram and memory generalization induced by stress. Glucocorticoid receptor antagonists, endocannabinoid synthesis inhibitors, increasing PV+ neuronal activity, and knocking down cannabinoid receptors in lateral amygdala PV+ neurons restored threat memory specificity and a sparse engram in stressed mice. These findings offer insights into stress-induced memory alterations, providing potential therapeutic avenues for stress-related disorders.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39549697/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39549697</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.034>10.1016/j.cell.2024.10.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39549697</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Sylvie L Lesuis</dc:creator>
<dc:creator>Sungmo Park</dc:creator>
<dc:creator>Annelies Hoorn</dc:creator>
<dc:creator>Asim J Rashid</dc:creator>
<dc:creator>Andrew J Mocle</dc:creator>
<dc:creator>Eric W Salter</dc:creator>
<dc:creator>Stefan Vislavski</dc:creator>
<dc:creator>Madison T Gray</dc:creator>
<dc:creator>Angelica M Torelli</dc:creator>
<dc:creator>Antonietta DeCristofaro</dc:creator>
<dc:creator>Wouter P F Driever</dc:creator>
<dc:creator>Mario van der Stelt</dc:creator>
<dc:creator>Larry S Zweifel</dc:creator>
<dc:creator>Graham L Collingridge</dc:creator>
<dc:creator>Julie L Lefebvre</dc:creator>
<dc:creator>Brandon J Walters</dc:creator>
<dc:creator>Paul W Frankland</dc:creator>
<dc:creator>Matthew N Hill</dc:creator>
<dc:creator>Sheena A Josselyn</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Stress disrupts engram ensembles in lateral amygdala to generalize threat memory in mice</dc:title>
<dc:identifier>pmid:39549697</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.034</dc:identifier>
</item>
<item>
<title>Functional genomics of human skeletal development and the patterning of height heritability</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39549696/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>Underlying variation in height are regulatory changes to chondrocytes, cartilage cells comprising long-bone growth plates. Currently, we lack knowledge on epigenetic regulation and gene expression of chondrocytes sampled across the human skeleton, and therefore we cannot understand basic regulatory mechanisms controlling height biology. We first rectify this issue by generating extensive epigenetic and transcriptomic maps from chondrocytes sampled from different growth plates across developing...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 7:S0092-8674(24)01256-X. doi: 10.1016/j.cell.2024.10.040. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Underlying variation in height are regulatory changes to chondrocytes, cartilage cells comprising long-bone growth plates. Currently, we lack knowledge on epigenetic regulation and gene expression of chondrocytes sampled across the human skeleton, and therefore we cannot understand basic regulatory mechanisms controlling height biology. We first rectify this issue by generating extensive epigenetic and transcriptomic maps from chondrocytes sampled from different growth plates across developing human skeletons, discovering novel regulatory networks shaping human bone/joint development. Next, using these maps in tandem with height genome-wide association study (GWAS) signals, we disentangle the regulatory impacts that skeletal element-specific versus global-acting variants have on skeletal growth, revealing the prime importance of regulatory pleiotropy in controlling height variation. Finally, as height is highly heritable, and thus often the test case for complex-trait genetics, we leverage these datasets within a testable omnigenic model framework to discover novel chondrocyte developmental modules and peripheral-acting factors shaping height biology and skeletal growth.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39549696/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39549696</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.040>10.1016/j.cell.2024.10.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39549696</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Daniel Richard</dc:creator>
<dc:creator>Pushpanathan Muthuirulan</dc:creator>
<dc:creator>Mariel Young</dc:creator>
<dc:creator>Loic Yengo</dc:creator>
<dc:creator>Sailaja Vedantam</dc:creator>
<dc:creator>Eirini Marouli</dc:creator>
<dc:creator>Eric Bartell</dc:creator>
<dc:creator>GIANT Consortium</dc:creator>
<dc:creator>Joel Hirschhorn</dc:creator>
<dc:creator>Terence D Capellini</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Functional genomics of human skeletal development and the patterning of height heritability</dc:title>
<dc:identifier>pmid:39549696</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.040</dc:identifier>
</item>
<item>
<title>Heart Failure in Zero Gravity-External Constraint and Cardiac Hemodynamics</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39549275/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2024 Nov 16. doi: 10.1001/jamacardio.2024.4596. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39549275/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39549275</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2024.4596>10.1001/jamacardio.2024.4596</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39549275</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>James P MacNamara</dc:creator>
<dc:creator>Christopher M Hearon</dc:creator>
<dc:creator>Giorgio Manferdelli</dc:creator>
<dc:creator>Aman M Shah</dc:creator>
<dc:creator>Kevin G Tayon</dc:creator>
<dc:creator>Ambarish Pandey</dc:creator>
<dc:creator>Satyam Sarma</dc:creator>
<dc:creator>Benjamin D Levine</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Heart Failure in Zero Gravity-External Constraint and Cardiac Hemodynamics</dc:title>
<dc:identifier>pmid:39549275</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2024.4596</dc:identifier>
</item>
<item>
<title>Temporal Effects of Plozasiran on Lipids and Lipoproteins in Persistent Chylomicronemia</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39549263/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2024 Nov 16. doi: 10.1161/CIRCULATIONAHA.124.072860. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39549263/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39549263</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072860>10.1161/CIRCULATIONAHA.124.072860</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39549263</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Gerald F Watts</dc:creator>
<dc:creator>Robert A Hegele</dc:creator>
<dc:creator>Robert S Rosenson</dc:creator>
<dc:creator>Ira J Goldberg</dc:creator>
<dc:creator>Antonio Gallo</dc:creator>
<dc:creator>Ann Mertens</dc:creator>
<dc:creator>Alexis Baass</dc:creator>
<dc:creator>Rong Zhou</dc:creator>
<dc:creator>Ma'an Muhsin</dc:creator>
<dc:creator>Jennifer Hellawell</dc:creator>
<dc:creator>Daniel Gaudet</dc:creator>
<dc:creator>Nicholas J Leeper</dc:creator>
<dc:creator>PALISADE Study Group</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Temporal Effects of Plozasiran on Lipids and Lipoproteins in Persistent Chylomicronemia</dc:title>
<dc:identifier>pmid:39549263</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072860</dc:identifier>
</item>
<item>
<title>Family matters: health policies to tackle cardiomyopathies across Europe</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39548843/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 16:ehae419. doi: 10.1093/eurheartj/ehae419. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39548843/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39548843</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae419>10.1093/eurheartj/ehae419</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39548843</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Iacopo Olivotto</dc:creator>
<dc:creator>Cardiomyopathies Matter Initiative</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Family matters: health policies to tackle cardiomyopathies across Europe</dc:title>
<dc:identifier>pmid:39548843</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae419</dc:identifier>
</item>
<item>
<title>Revascularization in frail patients with acute coronary syndromes: a retrospective longitudinal study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39548842/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Frailty is common in people presenting with ACS, where cardiovascular causes are the principal mode of death. Revascularization is associated with short- and long-term survival benefits in people at intermediate and high risk of frailty after adjustment for measured and unmeasured confounders.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Nov 16:ehae755. doi: 10.1093/eurheartj/ehae755. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Frailty is increasingly prevalent in people presenting with acute coronary syndrome (ACS). This high-risk group is typically excluded from trials of interventions in ACS, and there is uncertainty about the risks and benefits of invasive management.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Patients with an ACS diagnosis between 2010 and 2015 in England were identified from Hospital Episode Statistics, with linked Office for National Statistics mortality data. Frailty was defined by the Hospital Frailty Risk Score. Causal inference analysis used regional variation in revascularization as an instrumental variable to estimate average treatment effects of revascularization on cardiovascular mortality up to 5 years in people presenting with ACS and low-, intermediate-, or high-risk frailty.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The analysis included 565 378 ACS patients, of whom 11.6% (n = 65 522) were at intermediate risk and 4.7% (n = 26 504) were at high risk of frailty. Intermediate and high frailty risks were associated with reduced likelihood of echocardiography, invasive angiography, or revascularization and increased likelihood of mortality and major adverse cardiovascular events compared with low frailty risk. Cardiovascular death at 5 years was 78.6%, 77.3%, and 75.7% in people at low, intermediate, and high frailty risk, respectively. Instrumental variable analysis suggested that revascularization resulted in a higher absolute reduction in cardiovascular mortality in high and intermediate frail risk patients compared with low risk at 1-year post-ACS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Frailty is common in people presenting with ACS, where cardiovascular causes are the principal mode of death. Revascularization is associated with short- and long-term survival benefits in people at intermediate and high risk of frailty after adjustment for measured and unmeasured confounders.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39548842/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39548842</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae755>10.1093/eurheartj/ehae755</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39548842</guid>
<pubDate>Sat, 16 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Marius Roman</dc:creator>
<dc:creator>Joanne Miksza</dc:creator>
<dc:creator>Florence Yuk-Lin Lai</dc:creator>
<dc:creator>Shirley Sze</dc:creator>
<dc:creator>Katrina Poppe</dc:creator>
<dc:creator>Rob Doughty</dc:creator>
<dc:creator>Iain Squire</dc:creator>
<dc:creator>Gavin James Murphy</dc:creator>
<dc:date>2024-11-16</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Revascularization in frail patients with acute coronary syndromes: a retrospective longitudinal study</dc:title>
<dc:identifier>pmid:39548842</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae755</dc:identifier>
</item>
<item>
<title>Trials and tribulations of cell therapy for heart failure: an update on ongoing trials</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39548233/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>Heart failure (HF) remains a leading cause of mortality, responsible for 13% of all deaths worldwide. The prognosis for patients with HF is poor, with only a 50% survival rate within 5 years. A major challenge of ischaemia-driven HF is the loss of cardiomyocytes, compounded by the minimal regenerative capacity of the adult heart. To date, replacement of irreversibly damaged heart muscle can only be achieved by complete heart transplantation. In the past 20 years, cell therapy has emerged and...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Nat Rev Cardiol. 2024 Nov 15. doi: 10.1038/s41569-024-01098-8. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Heart failure (HF) remains a leading cause of mortality, responsible for 13% of all deaths worldwide. The prognosis for patients with HF is poor, with only a 50% survival rate within 5 years. A major challenge of ischaemia-driven HF is the loss of cardiomyocytes, compounded by the minimal regenerative capacity of the adult heart. To date, replacement of irreversibly damaged heart muscle can only be achieved by complete heart transplantation. In the past 20 years, cell therapy has emerged and evolved as a promising avenue for cardiac repair and regeneration. During this time, cell therapy for HF has encountered substantial barriers in both preclinical studies and clinical trials but the field continues to progress and evolve from lessons learned from such research. In this Review, we provide an overview of ongoing trials of cell-based and cell product-based therapies for the treatment of HF. Findings from these trials will facilitate the clinical translation of cardiac regenerative and reparative therapies not only by evaluating the safety and efficacy of specific cell-based therapeutics but also by establishing the feasibility of novel or underexplored treatment protocols such as repeated intravenous dosing, personalized patient selection based on pharmacogenomics, systemic versus intramural cell delivery, and epicardial engraftment of engineered tissue products.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39548233/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39548233</a> | DOI:<a href=https://doi.org/10.1038/s41569-024-01098-8>10.1038/s41569-024-01098-8</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39548233</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jianyi Jay Zhang</dc:creator>
<dc:creator>Steven M Pogwizd</dc:creator>
<dc:creator>Keiichi Fukuda</dc:creator>
<dc:creator>Wolfram-Hubertus Zimmermann</dc:creator>
<dc:creator>Chengming Fan</dc:creator>
<dc:creator>Joshua M Hare</dc:creator>
<dc:creator>Roberto Bolli</dc:creator>
<dc:creator>Philippe Menasché</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Nature reviews. Cardiology</dc:source>
<dc:title>Trials and tribulations of cell therapy for heart failure: an update on ongoing trials</dc:title>
<dc:identifier>pmid:39548233</dc:identifier>
<dc:identifier>doi:10.1038/s41569-024-01098-8</dc:identifier>
</item>
<item>
<title>STK19 facilitates the clearance of lesion-stalled RNAPII during transcription-coupled DNA repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547229/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>Transcription-coupled DNA repair (TCR) removes bulky DNA lesions impeding RNA polymerase II (RNAPII) transcription. Recent studies have outlined the stepwise assembly of TCR factors CSB, CSA, UVSSA, and transcription factor IIH (TFIIH) around lesion-stalled RNAPII. However, the mechanism and factors required for the transition to downstream repair steps, including RNAPII removal to provide repair proteins access to the DNA lesion, remain unclear. Here, we identify STK19 as a TCR factor...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 11:S0092-8674(24)01200-5. doi: 10.1016/j.cell.2024.10.018. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Transcription-coupled DNA repair (TCR) removes bulky DNA lesions impeding RNA polymerase II (RNAPII) transcription. Recent studies have outlined the stepwise assembly of TCR factors CSB, CSA, UVSSA, and transcription factor IIH (TFIIH) around lesion-stalled RNAPII. However, the mechanism and factors required for the transition to downstream repair steps, including RNAPII removal to provide repair proteins access to the DNA lesion, remain unclear. Here, we identify STK19 as a TCR factor facilitating this transition. Loss of STK19 does not impact initial TCR complex assembly or RNAPII ubiquitylation but delays lesion-stalled RNAPII clearance, thereby interfering with the downstream repair reaction. Cryoelectron microscopy (cryo-EM) and mutational analysis reveal that STK19 associates with the TCR complex, positioning itself between RNAPII, UVSSA, and CSA. The structural insights and molecular modeling suggest that STK19 positions the ATPase subunits of TFIIH onto DNA in front of RNAPII. Together, these findings provide new insights into the factors and mechanisms required for TCR.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547229/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39547229</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.018>10.1016/j.cell.2024.10.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547229</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Diana van den Heuvel</dc:creator>
<dc:creator>Marta Rodríguez-Martínez</dc:creator>
<dc:creator>Paula J van der Meer</dc:creator>
<dc:creator>Nicolas Nieto Moreno</dc:creator>
<dc:creator>Jiyoung Park</dc:creator>
<dc:creator>Hyun-Suk Kim</dc:creator>
<dc:creator>Janne J M van Schie</dc:creator>
<dc:creator>Annelotte P Wondergem</dc:creator>
<dc:creator>Areetha D'Souza</dc:creator>
<dc:creator>George Yakoub</dc:creator>
<dc:creator>Anna E Herlihy</dc:creator>
<dc:creator>Krushanka Kashyap</dc:creator>
<dc:creator>Thierry Boissière</dc:creator>
<dc:creator>Jane Walker</dc:creator>
<dc:creator>Richard Mitter</dc:creator>
<dc:creator>Katja Apelt</dc:creator>
<dc:creator>Klaas de Lint</dc:creator>
<dc:creator>Idil Kirdök</dc:creator>
<dc:creator>Mats Ljungman</dc:creator>
<dc:creator>Rob M F Wolthuis</dc:creator>
<dc:creator>Patrick Cramer</dc:creator>
<dc:creator>Orlando D Schärer</dc:creator>
<dc:creator>Goran Kokic</dc:creator>
<dc:creator>Jesper Q Svejstrup</dc:creator>
<dc:creator>Martijn S Luijsterburg</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>STK19 facilitates the clearance of lesion-stalled RNAPII during transcription-coupled DNA repair</dc:title>
<dc:identifier>pmid:39547229</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.018</dc:identifier>
</item>
<item>
<title>STK19 positions TFIIH for cell-free transcription-coupled DNA repair</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547228/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>In transcription-coupled nucleotide excision repair (TC-NER), stalled RNA polymerase II (RNA Pol II) binds CSB and CRL4^(CSA), which cooperate with UVSSA and ELOF1 to recruit TFIIH. To explore the mechanism of TC-NER, we recapitulated this reaction in vitro. When a plasmid containing a site-specific lesion is transcribed in frog egg extract, error-free repair is observed that depends on CSB, CRL4^(CSA), UVSSA, and ELOF1. Repair also requires STK19, a factor previously implicated in transcription...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 12:S0092-8674(24)01202-9. doi: 10.1016/j.cell.2024.10.020. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In transcription-coupled nucleotide excision repair (TC-NER), stalled RNA polymerase II (RNA Pol II) binds CSB and CRL4<sup>CSA</sup>, which cooperate with UVSSA and ELOF1 to recruit TFIIH. To explore the mechanism of TC-NER, we recapitulated this reaction in vitro. When a plasmid containing a site-specific lesion is transcribed in frog egg extract, error-free repair is observed that depends on CSB, CRL4<sup>CSA</sup>, UVSSA, and ELOF1. Repair also requires STK19, a factor previously implicated in transcription recovery after UV exposure. A 1.9-Å cryo-electron microscopy structure shows that STK19 binds the TC-NER complex through CSA and the RPB1 subunit of RNA Pol II. Furthermore, AlphaFold predicts that STK19 interacts with the XPD subunit of TFIIH, and disrupting this interface impairs cell-free repair. Molecular modeling suggests that STK19 positions TFIIH ahead of RNA Pol II for lesion verification. Our analysis of cell-free TC-NER suggests that STK19 couples RNA Pol II stalling to downstream repair events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547228/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39547228</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.020>10.1016/j.cell.2024.10.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547228</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Tycho E T Mevissen</dc:creator>
<dc:creator>Maximilian Kümmecke</dc:creator>
<dc:creator>Ernst W Schmid</dc:creator>
<dc:creator>Lucas Farnung</dc:creator>
<dc:creator>Johannes C Walter</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>STK19 positions TFIIH for cell-free transcription-coupled DNA repair</dc:title>
<dc:identifier>pmid:39547228</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.020</dc:identifier>
</item>
<item>
<title>SnapShot: Targeted protein degradation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547212/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>Targeted protein degradation strategies leverage endogenous cellular degradation machinery to selectively eliminate a protein of interest. Emerging technologies are opening avenues in drug discovery and functional characterization of intracellular, membrane, and extracellular proteins. To view this SnapShot, open or download the PDF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 14;187(23):6784-6784.e1. doi: 10.1016/j.cell.2024.10.025.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Targeted protein degradation strategies leverage endogenous cellular degradation machinery to selectively eliminate a protein of interest. Emerging technologies are opening avenues in drug discovery and functional characterization of intracellular, membrane, and extracellular proteins. To view this SnapShot, open or download the PDF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547212/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39547212</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.025>10.1016/j.cell.2024.10.025</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547212</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Yu Ding</dc:creator>
<dc:creator>Boxun Lu</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>SnapShot: Targeted protein degradation</dc:title>
<dc:identifier>pmid:39547212</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.025</dc:identifier>
</item>
<item>
<title>Bound by the love for cholesterol: A transporter meets a GPCR</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547211/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>In a recently published article in Nature, Bayly-Jones et al. report the cryo-EM structures of a lysosomal cholesterol sensor, LYCHOS, also known as GPR155, which reveals a unique fusion of a plant auxin-transporter-like domain with a seven-transmembrane GPCR-like domain and elucidates mechanistic insights into cellular regulation of mTORC1 activity.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 14;187(23):6518-6520. doi: 10.1016/j.cell.2024.10.033.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">In a recently published article in Nature, Bayly-Jones et al. report the cryo-EM structures of a lysosomal cholesterol sensor, LYCHOS, also known as GPR155, which reveals a unique fusion of a plant auxin-transporter-like domain with a seven-transmembrane GPCR-like domain and elucidates mechanistic insights into cellular regulation of mTORC1 activity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547211/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39547211</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.033>10.1016/j.cell.2024.10.033</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547211</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Divyanshu Tiwari</dc:creator>
<dc:creator>Nabarun Roy</dc:creator>
<dc:creator>Arun K Shukla</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Bound by the love for cholesterol: A transporter meets a GPCR</dc:title>
<dc:identifier>pmid:39547211</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.033</dc:identifier>
</item>
<item>
<title>Discovery and significance of protein-protein interactions in health and disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39547210/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20241117151114&amp;v=2.18.0.post9+e462414
      <description>The identification of individual protein-protein interactions (PPIs) began more than 40 years ago, using protein affinity chromatography and antibody co-immunoprecipitation. As new technologies emerged, analysis of PPIs increased to a genome-wide scale with the introduction of intracellular tagging methods, affinity purification (AP) followed by mass spectrometry (MS), and co-fractionation MS (CF-MS). Now, combining the resulting catalogs of interactions with complementary methods, including...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Nov 14;187(23):6501-6517. doi: 10.1016/j.cell.2024.10.038.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The identification of individual protein-protein interactions (PPIs) began more than 40 years ago, using protein affinity chromatography and antibody co-immunoprecipitation. As new technologies emerged, analysis of PPIs increased to a genome-wide scale with the introduction of intracellular tagging methods, affinity purification (AP) followed by mass spectrometry (MS), and co-fractionation MS (CF-MS). Now, combining the resulting catalogs of interactions with complementary methods, including crosslinking MS (XL-MS) and cryogenic electron microscopy (cryo-EM), helps distinguish direct interactions from indirect ones within the same or between different protein complexes. These powerful approaches and the promise of artificial intelligence applications like AlphaFold herald a future where PPIs and protein complexes, including energy-driven protein machines, will be understood in exquisite detail, unlocking new insights in the contexts of both basic biology and disease.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39547210/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20241117151114&v=2.18.0.post9+e462414">39547210</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.10.038>10.1016/j.cell.2024.10.038</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39547210</guid>
<pubDate>Fri, 15 Nov 2024 06:00:00 -0500</pubDate>
<dc:creator>Jack F Greenblatt</dc:creator>
<dc:creator>Bruce M Alberts</dc:creator>
<dc:creator>Nevan J Krogan</dc:creator>
<dc:date>2024-11-15</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Discovery and significance of protein-protein interactions in health and disease</dc:title>
<dc:identifier>pmid:39547210</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.10.038</dc:identifier>
</item>





























</channel>
</rss>